Subsequent Events (Details Narrative) ft² in Thousands |
1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apr. 06, 2025
USD ($)
|
Apr. 06, 2025
ILS (₪)
|
Mar. 31, 2025
shares
|
Mar. 26, 2025
USD ($)
|
Mar. 11, 2025
USD ($)
shares
|
Feb. 16, 2025
USD ($)
|
Feb. 16, 2025
ILS (₪)
|
Feb. 28, 2025
USD ($)
|
Feb. 28, 2025
ILS (₪)
|
Jan. 31, 2025
USD ($)
|
Jan. 31, 2025
ILS (₪)
|
Mar. 31, 2025
USD ($)
shares
|
Mar. 31, 2024
USD ($)
|
Dec. 31, 2024
USD ($)
ft²
|
Dec. 31, 2024
ILS (₪)
ft²
|
Dec. 31, 2023
USD ($)
|
Dec. 31, 2023
ILS (₪)
|
|
| Short term loan | $ 39,000 | ||||||||||||||||
| Shares issued | shares | 1,000,000 | ||||||||||||||||
| Proceeds from debt finincing | $ 31,000 | ||||||||||||||||
| Lease facilities area | ft² | 130 | 130 | |||||||||||||||
| ISRAEL | |||||||||||||||||
| Severance pay for employees | $ 71,000 | ₪ 263,000 | $ 113,000 | ₪ 415,000 | |||||||||||||
| Equity Purchase Agreement [Member] | |||||||||||||||||
| Investment amount | $ 15,000,000 | ||||||||||||||||
| Investment put notice amount | $ 500,000 | ||||||||||||||||
| Equity Purchase Agreement [Member] | Common Stock [Member] | |||||||||||||||||
| Shares issued | shares | 1,000,000 | ||||||||||||||||
| Maximum percentage of shares outstanding | 9.99% | ||||||||||||||||
| Purchase Agreement [Member] | |||||||||||||||||
| Bear interest rate | 9.00% | ||||||||||||||||
| Debt face amount | $ 31,200 | ||||||||||||||||
| Unsecured principal amount | 10,400 | ||||||||||||||||
| Proceeds from debt finincing | $ 100,000 | ||||||||||||||||
| Bank Hapoalim [Member] | |||||||||||||||||
| Bear interest rate | 9.00% | 9.00% | |||||||||||||||
| Two Officers [Member] | |||||||||||||||||
| Salaries | $ 2,740 | ₪ 10,000 | $ 1,644 | ₪ 6,000 | |||||||||||||
| Subsequent Event [Member] | Equity Purchase Agreement [Member] | |||||||||||||||||
| Investment amount | $ 15,000,000,000 | ||||||||||||||||
| Investment put notice amount | $ 500,000,000 | ||||||||||||||||
| Subsequent Event [Member] | Equity Purchase Agreement [Member] | Common Stock [Member] | |||||||||||||||||
| Shares issued | shares | 1,000,000,000 | ||||||||||||||||
| Maximum percentage of shares outstanding | 9.99% | ||||||||||||||||
| Subsequent Event [Member] | Purchase Agreement [Member] | |||||||||||||||||
| Bear interest rate | 9.00% | ||||||||||||||||
| Debt face amount | $ 31,200,000 | ||||||||||||||||
| Proceeds from debt finincing | 100,000,000 | ||||||||||||||||
| Subsequent Event [Member] | Purchase Agreement [Member] | Notes [Member] | |||||||||||||||||
| Unsecured principal amount | $ 10,400,000 | ||||||||||||||||
| Subsequent Event [Member] | Bank Hapoalim [Member] | |||||||||||||||||
| Short term loan | $ 38,000,000 | ₪ 140,000,000 | |||||||||||||||
| Bear interest rate | 9.00% | 9.00% | |||||||||||||||
| Debt repayable terms | repayable in two equal installments on April 30, 2025, and May 31, 2025. In March 2025 | repayable in two equal installments on April 30, 2025, and May 31, 2025. In March 2025 | |||||||||||||||
| Subsequent Event [Member] | Director [Member] | Warrant [Member] | |||||||||||||||||
| Shares issued | shares | 3,636,634,000 | ||||||||||||||||
| Subsequent Event [Member] | Minimum [Member] | |||||||||||||||||
| Royalty percentage | 3.00% | 3.00% | |||||||||||||||
| Subsequent Event [Member] | Minimum [Member] | Two Officers [Member] | |||||||||||||||||
| Salaries | $ 1,644,000 | ₪ 6,000,000 | |||||||||||||||
| Subsequent Event [Member] | Maximum [Member] | |||||||||||||||||
| Royalty percentage | 5.00% | 5.00% | |||||||||||||||
| Subsequent Event [Member] | Maximum [Member] | Two Officers [Member] | |||||||||||||||||
| Salaries | $ 2,740,000 | ₪ 10,000,000 | |||||||||||||||
| Subsequent Event [Member] | Israel Innovation Authority [Member] | |||||||||||||||||
| Project, description | the Israeli Innovation Authority (the “IIA”) to fund the development of a device for the assessment of diabetic foot ulcers before skin breakage among diabetic patients. The IIA approved the Company’s program with a budget in total amount NIS 4,603,938 (approximately $1,222,786), which includes a grant of 40% or NIS 1,841,575 (approximately $489,035). | the Israeli Innovation Authority (the “IIA”) to fund the development of a device for the assessment of diabetic foot ulcers before skin breakage among diabetic patients. The IIA approved the Company’s program with a budget in total amount NIS 4,603,938 (approximately $1,222,786), which includes a grant of 40% or NIS 1,841,575 (approximately $489,035). | |||||||||||||||
| Subsequent Event [Member] | Israel Innovation Authority [Member] | |||||||||||||||||
| Advance received from affiliate | $ 171,468 | ₪ 644,551 | |||||||||||||||